These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10461095)

  • 21. [8-methoxypsoralen serum content of problem patients in PUVA therapy].
    Walther T; Haustein UF
    Dermatol Monatsschr; 1990; 176(5-6):317-21. PubMed ID: 2227049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
    Nørgaard M; Hueg B; Staberg B
    Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment.
    Sakuntabhai A; Diffey BL; Farr PM
    Br J Dermatol; 1995 Dec; 133(6):919-23. PubMed ID: 8547045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoemulsion containing 8-methoxypsoralen for topical treatment of dermatoses: Development, characterization and ex vivo permeation in porcine skin.
    Oliveira CA; Gouvêa MM; Antunes GR; Freitas ZMF; Marques FFC; Ricci-Junior E
    Int J Pharm; 2018 Aug; 547(1-2):1-9. PubMed ID: 29800737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PUVA-cream photochemotherapy for the treatment of localized scleroderma.
    Grundmann-Kollmann M; Ochsendorf F; Zollner TM; Spieth K; Sachsenberg-Studer E; Kaufmann R; Podda M
    J Am Acad Dermatol; 2000 Oct; 43(4):675-8. PubMed ID: 11004625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 8-Methoxypsoralen serum levels in poor responders to photochemotherapy. Importance of drug formulation and individual factors.
    Walther T; Haustein UF
    Int J Dermatol; 1991 Jul; 30(7):516-8. PubMed ID: 1769779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The pharmacokinetic and toxicologic profile of 8-methoxypsoralen. The basis for safe and effective PUVA therapy].
    Schmid J; Brickl R; Koss FW
    Derm Beruf Umwelt; 1988; 36(6):177-85. PubMed ID: 3069432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
    Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
    Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.
    Asawanonda P; Amornpinyokeit N; Nimnuan C
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):50-5. PubMed ID: 18181973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.
    Hofer A; Fink-Puches R; Kerl H; Quehenberger F; Wolf P
    Photodermatol Photoimmunol Photomed; 2006 Feb; 22(1):1-5. PubMed ID: 16436174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burns caused by accidental overdose of photochemotherapy (PUVA).
    Herr H; Cho HJ; Yu S
    Burns; 2007 May; 33(3):372-5. PubMed ID: 17218059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
    Shephard SE; Panizzon RG
    Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
    Man I; McKinlay J; Dawe RS; Ferguson J; Ibbotson SH
    J Am Acad Dermatol; 2003 Jul; 49(1):59-64. PubMed ID: 12833009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction between 8-methoxypsoralen and phenytoin. Consequence for PUVA therapy.
    Staberg B; Hueg B
    Acta Derm Venereol; 1985; 65(6):553-5. PubMed ID: 2420126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
    Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases.
    Teimouri A; Yeung P; Agu RU
    Int J Pharm Compd; 2021; 25(4):344-351. PubMed ID: 34297697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
    Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
    Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.